ABSTRACT
Abnormal expression of Vasorin (VASN) is related to many types of cancer, but the signaling pathway and mechanism of how VASN contributes to the carcinogenesis of hepatocellular carcinoma (HCC) are poorly understood. Here, we found that VASN was up-regulated in serum/serum exosome and tissues of HCC patients. The expression of VASN in serum improve the detection rate of HCC in alpha-fetoprotein-negative HCC patients. Immunohistochemistry revealed that VASN was highly expressed in HCC tissues and associated with different stages of HCC. Noticeably, when serum VASN combined with α-fetoprotein, the area under the curve (AUC), sensitivity, and specificity of HCC patients compared with healthy patients reached 0.918 (95% CI: 0.869-0.967, P < 0.001), 90.91%, and 90.20%, respectively. VASN knockout HCC cells were obtained by CRISPR/Cas9 and a VASN-specific monoclonal antibody was prepared by hybridoma technology. Knockout of VASN or the addition of VASN-specific monoclonal antibody suppressed the proliferation and migration of HCC. Mechanistically, VASN promote the proliferation and migration of HCC by regulating the phosphorylation of STAT3 and the expression of downstream genes CCND1 and MMP2. In conclusion, our findings suggest that VASN plays a crucial role in the activation of STAT3 signaling pathway in HCC, which is a promising target for the diagnosis and therapy of HCC.
Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Humans , alpha-Fetoproteins/metabolism , Antibodies, Monoclonal/metabolism , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Cell Proliferation/physiology , Liver Neoplasms/pathology , Signal Transduction , STAT3 Transcription Factor/metabolismABSTRACT
Background: Metastasis is the major cause of high recurrence and mortality of hepatocellular carcinoma (HCC). Unfortunately, there are few reports on effective biomarkers of HCC metastasis. Previous studies have reported that SAA1 may be a predictor and prognostic biomarker for multiple malignant tumors. However, the role of SAA1 in HCC has not yet been investigated. Methods: We applied RNA sequencing and proteomics analysis to investigate the expression landscape of HCC cell lines and patient serum, respectively. SAA1 is a common key gene and listed as a candidate biomarker of HCC metastasis. It was validated in two cell lines, 107 participants serum, and 63 matched HCC and adjacent non-tumorous liver tissues. Human Protein Atlas (HPA), Genotype-Tissue Expression (GTEx), and The Cancer Genome Atlas (TCGA) datasets were integrated to explore SAA1 expression among various cell types and organs. The diagnostic and prognostic value of SAA1 in HCC were determined through receiver operating characteristic (ROC) and Kaplan-Meier curves. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and protein-protein interaction (PPI) network were constructed for SAA1, as well as for its co-expressed genes. We further analyzed the correlation between SAA1 and co-expression genes. Results: We found 7 differentially expressed genes (DEGs) and 14 differentially expressed proteins (DEPs) were related to HCC metastasis. SAA1, a key candidate biomarker, was highly enriched in hepatocytes and liver organ, and it was also highly expressed in HCC cells and the serum and tissues of HCC patients. The results of ROC curve analysis indicated that SAA1 had better predictive values for distinguishing HCC metastasis from non-metastasis. Kaplan-Meier curve analysis revealed that HCC patients with higher SAA1 expression had worse overall survival. Conclusions: Our findings provide new insights into HCC metastasis by identifying candidate gene prediction biomarkers for HCC metastasis.
ABSTRACT
The expression level of retinol-binding protein 4 (RBP4) protein is closely related to liver damage and plays an important role in the diagnosis and prognosis of cancer. However, the preparation of anti-RBP4 mAb or exploration on the application of anti-RBP4 mAb has not been reported thus far. In the present study, we constructed a pET30a-RBP4 recombinant vector, used E. coli BL21 (DE3) as the vector to express the RBP4 recombinant protein and prepared anti-RBP4 mAb using hybridoma technology. We performed immunohistochemical analysis on hepatocellular carcinoma (HCC) and adjacent tissues by using this anti-RBP4 mAb. In addition to the high-purity RBP4 recombinant protein, we successfully developed the anti-RBP4 mAb with high affinity and specificity; it binds to natural RBP4 protein and is suitable for immunohistochemical analysis.
Subject(s)
Carcinoma, Hepatocellular , Liver Neoplasms , Antibodies, Monoclonal , Carcinoma, Hepatocellular/genetics , Escherichia coli/metabolism , Humans , Liver Neoplasms/genetics , Recombinant Proteins/genetics , Retinol-Binding Proteins, Plasma/genetics , Retinol-Binding Proteins, Plasma/metabolismABSTRACT
The protective effect of antioxidant peptides from grass carp scale gelatin on hydrogen peroxide (H2O2)-mediated oxidative injured HepG2 cells was investigated, and the protective mechanism as well as peptide structure were studied. Pretreated with grass carp scale gelatin hydrolysates (GSGH) for 24 h significantly increased the survival rates and decreased the apoptosis rates of H2O2-mediated oxidative injured HepG2 cells. The increase in SOD, CAT and GPX activities, reduce in ROS level and MDA content, and weaken in damage on cell membrane and DNA could be responsible for the protective effect of GSGH on H2O2-mediated oxidative injured HepG2 cells. Peptide sequences of GSGH were analyzed by LC-ESI-Q-Orbitrap-MS/MS, and results showed that most of them were low molecular weight peptide at 358-986 Da. Synergistic effect existed among antioxidant peptides and contributed to the strong antioxidant activities of GSGH.
Subject(s)
Antioxidants , Carps , Animals , Antioxidants/metabolism , Antioxidants/pharmacology , Carps/metabolism , Cell Survival , Gelatin , Hep G2 Cells , Humans , Hydrogen Peroxide , Oxidative Stress , Peptides/pharmacology , Tandem Mass SpectrometryABSTRACT
A ratiometric fluorescence method based on carboxylated graphitic carbon nitride nanosheets (C-g-C3N4) and Eu3+ (C-g-C3N4-Eu3+) is described for the detection of tetracyclines (TCs), a broad-spectrum antibiotic. C-g-C3N4, which was used as a fluorescence enhancer of Eu3+, was prepared by direct pyrolysis of melamine and post-functionalization. In the presence of TCs, the fluorescence intensity of Eu3+ at 616 nm increased, accompanied by a decrease of fluorescence intensity of C-g-C3N4 at 435 nm. Under the optimal conditions, the ratio of fluorescence intensity at 616 nm to the one at 435 nm (I616/I415) increases linearly in the 10 nM to 40 µM TC concentration range with a detection limit of 7.7 nM (S/N = 3). It has been successfully applied in the detection of TCs in spiked tap water and soil samples with satisfactory recovery (96.6-107.2%) and high precision. Furthermore, a test paper and smartphone can assist in rapidly detecting TCs due to the emission color change from blue to red with the addition of TCs. This shows that the proposed method has great potential for the rapid detection TCs in real samples.
Subject(s)
Graphite , Tetracyclines , Anti-Bacterial Agents , Fluorescence , Nitrogen CompoundsABSTRACT
Aim: The aim was to systematically investigate the miRNA biomarkers for early diagnosis of hepatocellular carcinoma (HCC). Materials & methods: A systematic review and meta-analysis of miRNA expression in HCC were performed. Results: A total of 4903 cases from 30 original studies were comprehensively analyzed. The sensitivity and specificity of miR-224 in discriminating early-stage HCC patients from benign lesion patients were 0.868 and 0.792, which were superior to α-fetoprotein. Combined miR-224 with α-fetoprotein, the sensitivity and specificity were increased to 0.882 and 0.808. Prognostic survival analysis showed low expression of miR-125b and high expression of miR-224 were associated with poor prognosis. Conclusion: miR-224 had a prominent diagnostic efficiency in early-stage HCC, with miR-224 and miR-125b being valuable in the prognostic diagnosis.
Subject(s)
Carcinoma, Hepatocellular/genetics , MicroRNAs/genetics , Biomarkers, Tumor/genetics , Carcinoma, Hepatocellular/metabolism , Gene Expression/genetics , Gene Expression Regulation, Neoplastic/genetics , Humans , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , MicroRNAs/metabolism , Prognosis , ROC Curve , Sensitivity and Specificity , Transcriptome/genetics , alpha-Fetoproteins/genetics , alpha-Fetoproteins/metabolismABSTRACT
Exosomal long noncoding RNA (lncRNA) has been found to be associated with the development of cancers. However, the expression characteristics and the biological roles of exosomal lncRNAs in hepatocellular carcinoma (HCC) remain unknown. Here, by RNA sequencing, we found 9440 mRNAs and 8572 lncRNAs were differentially expressed (DE-) in plasma exosomes between HCC patients and healthy controls. Exosomal DE-lncRNAs displayed higher expression levels and tissue specificity, lower expression variability and splicing efficiency than DE-mRNAs. Six candidate DE-lncRNAs (fold change 6 or more, P ≤ .01) were high in HCC cells and cell exosomes. The knockdown of these candidate DE-lncRNAs significantly affected the migration, proliferation, and apoptosis in HCC cells. In particular, a novel DE-lncRNA, RP11-85G21.1 (lnc85), promoted HCC cellular proliferation and migration by targeted binding and regulating of miR-324-5p. More importantly, the level of serum lnc85 was highly expressed in both Alpha-fetoprotein (AFP)-positive and AFP-negative HCC patients and allowed distinguishing AFP-negative HCC from healthy control and liver cirrhosis (area under the receiver operating characteristic curve, 0.869; sensitivity, 80.0%; specificity, 76.5%) with high accuracy. Our finding offers a new insight into the association between the dysregulation of exosomal lncRNA and HCC, suggesting that lnc85 could be a potential biomarker of HCC.
Subject(s)
Biomarkers, Tumor , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/metabolism , Cell-Free Nucleic Acids , Exosomes/metabolism , Liver Neoplasms/genetics , Liver Neoplasms/metabolism , RNA, Long Noncoding/genetics , Adult , Alternative Splicing , Carcinoma, Hepatocellular/diagnosis , Female , Gene Expression Regulation, Neoplastic , High-Throughput Nucleotide Sequencing , Humans , Liver Neoplasms/diagnosis , Male , MicroRNAs , Middle Aged , Phenotype , RNA, Messenger , ROC Curve , Sequence Analysis, RNAABSTRACT
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. However, there is no complete effective (ideal) treatment for liver cancer yet, and the new methods are expected to be discovered. Herein, for the first time, we report the anti-HCC effects of copper-cysteamine nanoparticles (Cu-Cy NPs), a new type of photosensitizers. An in vitro 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay shows that Cu-Cy NPs could significantly reduce the activity of HepG2 cells at a very low dose after a short time of ultraviolet radiation. In addition, we found that cell death was induced by Cu-Cy NPs, which is associated with cellular apoptosis. This implied that apoptosis might be the main mechanism of the Cu-Cy's anti-HCC activity. Furthermore, we found that Cu-Cy NPs obviously inhibited the tumor growth in vivo. More interestingly, we found that the soluble Cu-Cy NPs were able to enter exosomes which were secreted by tumor cells, and exosomes could be used to deliver Cu-Cy NPs to target tumor cells. All these observations suggest that Cu-Cy NPs have a good potential for cancer treatment.
Subject(s)
Antineoplastic Agents/pharmacology , Copper , Cysteamine , Metal Nanoparticles , Photosensitizing Agents/pharmacology , Animals , Antineoplastic Agents/chemistry , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/metabolism , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Cell Survival/drug effects , Cell Survival/radiation effects , Copper/chemistry , Cysteamine/chemistry , Disease Models, Animal , Dose-Response Relationship, Drug , Exosomes/metabolism , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/metabolism , Liver Neoplasms/pathology , Metal Nanoparticles/chemistry , Metal Nanoparticles/ultrastructure , Mice , Photosensitizing Agents/chemistry , Singlet Oxygen/metabolism , Solubility , Ultraviolet Rays , Xenograft Model Antitumor AssaysABSTRACT
AIM: The aim was to systematically evaluate whether exosomal miRNAs could be regarded as potential minimally invasive biomarkers of diagnosis for gastrointestinal cancer. METHODS: A systematic review and meta analysis of exosomal miRNA expression in gastrointestinal cancer were performed. RESULTS: A total of 370 articles were retrieved from PubMed and EMBASE. The summary receiver operating characteristic curves of three miRNAs (miR-21, miR-1246 and miR-4644) were drawn, miR-21, miR-1246 and miR-4644 exhibited sensitivities of 0.66, 0.920 and 0.750, respectively; specificities were 0.87, 0.958 and 0.769, respectively; and areas under the curve for discriminating gastrointestinal cancer patients from control subjects were 0.876, 0.969 and 0.827, respectively. CONCLUSION: Exosome miR-1246 had the highest level of diagnostic efficiency, which indicated that miR-1246 could be a biomarker.